Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist

International Journal of Cardiology

Volumn 169, Issue 6, 2013, Pages 385-393

  Yin, Meimei ^a   Westenbrink, B Daan ^a   Meissner, Maxi ^a   Van Gilst, Wiek H ^a   De Boer, Rudolf A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiac remodeling; Diabetes; Heart failure; Metformin; Oral antidiabetic drugs; Sulfonylurea

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DISEASE MODEL; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; TRANSLATIONAL RESEARCH; TREATMENT INDICATION;

ANIMALS; CARDIOLOGY; DISEASE MODELS, ANIMAL; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL ISCHEMIA; PHYSICIANS; PROSPECTIVE STUDIES; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84887948455     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.10.005     Document Type: Review

References (100)

1. K.M. Narayan, J.P. Boyle, T.J. Thompson, S.W. Sorensen, and D.F. Williamson Lifetime risk for diabetes mellitus in the United States JAMA 290 2003 1884 1890
2. L. Ryden, E. Standl, and M. Bartnik Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136
3. S. Boudina, and E.D. Abel Diabetic cardiomyopathy revisited Circulation 115 2007 3213 3223
4. H. Ashrafian, M.P. Frenneaux, and L.H. Opie Metabolic mechanisms in heart failure Circulation 116 2007 434 448
5. P. De Groote, N. Lamblin, and F. Mouquet Impact of diabetes mellitus on long-term survival in patients with congestive heart failure Eur Heart J 25 2004 656 662
6. D.L. Dries, N.K. Sweitzer, M.H. Drazner, L.W. Stevenson, and B.J. Gersh Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction J Am Coll Cardiol 38 2001 421 428
7. R.A. de Boer, W. Doehner, and I.C. van der Horst Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or = 70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]) Am J Cardiol 106 2010 [78-86.e1]
8. W.B. Kannel, M. Hjortland, and W.P. Castelli Role of diabetes in congestive heart failure: the Framingham study Am J Cardiol 34 1974 29 34
9. L. Amato, G. Paolisso, and F. Cacciatore Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group Diabetes Metab 23 1997 213 218
10. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
11. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 854 865
12. D.T. Eurich, F.A. McAlister, and D.F. Blackburn Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review BMJ 335 2007 497
13. E.Z. Fisman, and A. Tenenbaum A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease Cardiovasc Diabetol 8 2009 38
14. S. El Messaoudi, G.A. Rongen, R.A. de Boer, and N.P. Riksen The cardioprotective effects of metformin Curr Opin Lipidol 22 2011 445 453
15. D.K. Ingram, M. Zhu, and J. Mamczarz Calorie restriction mimetics: an emerging research field Aging Cell 5 2006 97 108
16. R.J. Legtenberg, R.J. Houston, B. Oeseburg, and P. Smits Metformin improves cardiac functional recovery after ischemia in rats Horm Metab Res 34 2002 182 185
17. L. Solskov, B. Lofgren, and S.B. Kristiansen Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration Basic Clin Pharmacol Toxicol 103 2008 82 87
18. Y. Xing, N. Musi, and N. Fujii Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase J Biol Chem 278 2003 28372 28377
19. G.S. Bhamra, D.J. Hausenloy, and S.M. Davidson Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening Basic Res Cardiol 103 2008 274 284
20. J.W. Calvert, S. Gundewar, and S. Jha Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling Diabetes 57 2008 696 705
21. E. Kravchuk, E. Grineva, A. Bairamov, M. Galagudza, and T. Vlasov The effect of metformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus type II Exp Diabetes Res 2011 2011 907496
22. S. Gundewar, J.W. Calvert, and S. Jha Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure Circ Res 104 2009 403 411
23. Z. Xie, C. He, and M.H. Zou AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy Autophagy 7 2011 1254 1255
24. M. Yin, I.C. van der Horst, and J.P. van Melle Metformin improves cardiac function in a non-diabetic rat model of post-MI heart failure Am J Physiol Heart Circ Physiol 301 2011 H459 H468
25. X.F. Wang, J.Y. Zhang, L. Li, X.Y. Zhao, H.L. Tao, and L. Zhang Metformin improves cardiac function in rats via activation of AMP-activated protein kinase Clin Exp Pharmacol Physiol 38 2011 94 101
26. H. Sasaki, H. Asanuma, and M. Fujita Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase Circulation 119 2009 2568 2577
27. H. Xiao, X. Ma, and W. Feng Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway Cardiovasc Res 87 2010 504 513
28. J. Rosenstock, E. Samols, D.B. Muchmore, and J. Schneider Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group Diabetes Care 19 1996 1194 1199
29. M. Hiraoka, and T. Furukawa Functional modulation of cardiac ATP-sensitive K(+) channels News Physiol Sci 13 1998 131 137
30. T. Miura, and T. Miki ATP-sensitive K + channel openers: old drugs with new clinical benefits for the heart Curr Vasc Pharmacol 1 2003 251 258
31. P.A. Brady, and A. Terzic The sulfonylurea controversy: more questions from the heart J Am Coll Cardiol 31 1998 950 956
32. J.C. Docherty, H.E. Gunter, B. Kuzio, L. Shoemaker, L. Yang, and R. Deslauriers Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies J Mol Cell Cardiol 29 1997 1665 1673
33. I. Maruyama, Y. Tomiyama, and K. Maruyama Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts Eur J Pharmacol 531 2006 194 200
34. S. Kashimoto, A. Furuya, M. Kume, T. Yamaguchi, and T. Kumazawa Effects of glibenclamide on hydroxyl radical formation in the postischaemic reperfused heart with or without inhalation anaesthetics Eur J Anaesthesiol 18 2001 811 815
35. I. Namekata, Y. Yamaguchi, and S. Moriguchi (R)-ACX, a pancreatic beta-cell selective sulfonylurea, does not aggravate myocardial ischemia-reperfusion damage Eur J Pharmacol 577 2007 211 218
36. N.E. El-Reyani, I. Baczko, I. Lepran, and J.G. Papp Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats Acta Physiol Hung 87 2000 173 184
37. T.M. Lee, M.S. Lin, C.H. Tsai, and N.C. Chang Effects of pravastatin on ventricular remodeling by activation of myocardial KATP channels in infarcted rats: role of 70-kDa S6 kinase Basic Res Cardiol 102 2007 171 182
38. T.M. Lee, M.S. Lin, and N.C. Chang Effect of pravastatin on sympathetic reinnervation in postinfarcted rats Am J Physiol Heart Circ Physiol 293 2007 H3617 H3626
39. T.M. Lee, M.S. Lin, and N.C. Chang Effect of ATP-sensitive potassium channel agonists on ventricular remodeling in healed rat infarcts J Am Coll Cardiol 51 2008 1309 1318
40. K. Schoonjans, and J. Auwerx Thiazolidinediones: an update Lancet 355 2000 1008 1010
41. J.M. Olefsky Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists J Clin Invest 106 2000 467 472
42. O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat Endocrinology 137 1996 354 366
43. L. Petrazzi, D. Grassi, and L. Polidoro Cardiovascular risk and cardiometabolic protection: role of glitazones J Nephrol 21 2008 826 835
44. A.J. Krentz, and C.J. Bailey Oral antidiabetic agents: current role in type 2 diabetes mellitus Drugs 65 2005 385 411
45. H. Yki-Jarvinen Thiazolidinediones N Engl J Med 351 2004 1106 1118
46. P. Shah, and S. Mudaliar Pioglitazone: side effect and safety profile Expert Opin Drug Saf 9 2010 347 354
47. T.L. Yue Tl, J. Chen, and W. Bao In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone Circulation 104 2001 2588 2594
48. H. Ito, A. Nakano, M. Kinoshita, and A. Matsumori Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model Lab Invest 83 2003 1715 1721
49. N.S. Wayman, Y. Hattori, and M.C. McDonald Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size FASEB J 16 2002 1027 1040
50. T.M. Lee, and T.F. Chou Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins Am J Physiol Heart Circ Physiol 285 2003 H1650 H1659
51. A.M. Wynne, M.M. Mocanu, and D.M. Yellon Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK J Cardiovasc Pharmacol 46 2005 817 822
52. Y. Birnbaum, B. Long, J. Qian, J.R. Perez-Polo, and Y. Ye Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-gamma-independent manner Basic Res Cardiol 106 2011 431 446
53. Y. Ye, K.T. Keyes, C.F. Zhang, J.R. Perez-Polo, Y. Lin, and Y. Birnbaum Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size Cardiovasc Drugs Ther 24 2010 107 120
54. Y. Ye, Y. Lin, and S. Atar Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions Am J Physiol Heart Circ Physiol 291 2006 H1158 H1169
55. S. Yasuda, H. Kobayashi, and M. Iwasa Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction Am J Physiol Heart Circ Physiol 296 2009 H1558 H1565
56. X.J. Zhang, Z.B. Xiong, and A.L. Tang Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway Clin Exp Pharmacol Physiol 37 2010 156 161
57. J. Li, M.J. Lang, X.B. Mao, L. Tian, and Y.B. Feng Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of rat Cardiovasc Drugs Ther 22 2008 283 291
58. Y. Ye, Y. Lin, J.R. Perez-Polo, and Y. Birnbaum Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone Cardiovasc Drugs Ther 22 2008 429 436
59. M. Abe, Y. Takiguchi, S. Ichimaru, S. Kaji, K. Tsuchiya, and K. Wada Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method Eur J Pharmacol 589 2008 215 219
60. T. Shiomi, H. Tsutsui, and S. Hayashidani Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 106 2002 3126 3132
61. D.F. Geng, W. Wu, D.M. Jin, J.F. Wang, and Y.M. Wu Effect of peroxisome proliferator-activated receptor gamma ligand rosiglitazone on left ventricular remodeling in rats with myocardial infarction Int J Cardiol 113 2006 86 91
62. C.A. Lygate, K. Hulbert, M. Monfared, M.A. Cole, K. Clarke, and S. Neubauer The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction Cardiovasc Res 58 2003 632 637
63. S. Frantz, K. Hu, and J. Widder Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction Br J Pharmacol 141 2004 9 14
64. W. Linz, P. Wohlfart, and M. Baader The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats Acta Pharmacol Sin 30 2009 935 946
65. C.S. Weiss, M. Hagenmuller, and M. Pichler Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats Naunyn Schmiedebergs Arch Pharmacol 381 2010 285 295
66. H. Oeseburg, R.A. de Boer, H. Buikema, P. van der Harst, W.H. van Gilst, and H.H. Sillje Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A Arterioscler Thromb Vasc Biol 30 2010 1407 1414
67. R. Gros, X. You, and L.L. Baggio Cardiac function in mice lacking the glucagon-like peptide-1 receptor Endocrinology 144 2003 2242 2252
68. L.A. Nikolaidis, S. Mankad, and G.G. Sokos Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
69. G.G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, and R.P. Shannon Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 2006 694 699
70. A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, and D.M. Yellon Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 2005 146 151
71. A.K. Bose, M.M. Mocanu, R.D. Carr, and D.M. Yellon Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway Cardiovasc Drugs Ther 21 2007 253 256
72. A.K. Bose, M.M. Mocanu, R.D. Carr, and D.M. Yellon Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model Cardiovasc Drugs Ther 19 2005 9 11
73. D.P. Sonne, T. Engstrom, and M. Treiman Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart Regul Pept 146 2008 243 249
74. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
75. A. Ossum, U. van Deurs, T. Engstrom, J.S. Jensen, and M. Treiman The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart Pharmacol Res 60 2009 411 417
76. T. Zhao, P. Parikh, and S. Bhashyam Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts J Pharmacol Exp Ther 317 2006 1106 1113
77. M.H. Noyan-Ashraf, M.A. Momen, and K. Ban GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
78. J. Kristensen, U.M. Mortensen, M. Schmidt, P.H. Nielsen, T.T. Nielsen, and M. Maeng Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model BMC Cardiovasc Disord 9 2009 31
79. I. Poornima, S.B. Brown, S. Bhashyam, P. Parikh, H. Bolukoglu, and R.P. Shannon Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat Circ Heart Fail 1 2008 153 160
80. Q. Liu, C. Anderson, and A. Broyde Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure Cardiovasc Diabetol 9 2010 76
81. L.A. Nikolaidis, D. Elahi, and T. Hentosz Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 110 2004 955 961
82. G.M. Barakat, N. Nuwayri-Salti, L.N. Kadi, K.M. Bitar, W.A. Al-Jaroudi, and A.B. Bikhazi Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts Gen Physiol Biophys 30 2011 34 44
83. B. Huisamen, A. Genis, E. Marais, and A. Lochner Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats Cardiovasc Drugs Ther 25 2011 13 20
84. M. Sauve, K. Ban, and M.A. Momen Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 59 2010 1063 1073
85. Y. Ye, K.T. Keyes, C. Zhang, J.R. Perez-Polo, Y. Lin, and Y. Birnbaum The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA Am J Physiol Heart Circ Physiol 298 2010 H1454 H1465
86. M. Yin, H.H. Sillje, M. Meissner, W.H. van Gilst, and R.A. de Boer Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure Cardiovasc Diabetol 10 2011 85
87. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
88. T.K. Schramm, G.H. Gislason, A. Vaag, J.N. Rasmussen, F. Folke, M.L. Hansen, E.L. Fosbøl, L. Køber, M.L. Norgaard, M. Madsen, P.R. Hansen, and C. Torp-Pedersen Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study Eur Heart J 32 2011 1900 1908
89. D.T. Eurich, D.L. Weir, and S.R. Majumdar Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients Circ Heart Fail 6 2013 395 402
90. C.L. Roumie, A.M. Hung, and R.A. Greevy Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study Ann Intern Med 157 2012 601 610
91. H.S. Seltzer A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP) Diabetes 21 1972 976 979
92. S. Singh, Y.K. Loke, and C.D. Furberg Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 2007 1189 1195
93. E. Erdmann, B. Charbonnel, and R.G. Wilcox Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08) Diabetes Care 30 2007 2773 2778
94. P.D. Home, S.J. Pocock, and H. Beck-Nielsen Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N Engl J Med 357 2007 28 38
95. P.D. Home, S.J. Pocock, and H. Beck-Nielsen Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
96. S.E. Nissen, S.J. Nicholls, and K. Wolski Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573
97. J.R. Ussher, and D.J. Drucker Cardiovascular biology of the incretin system Endocr Rev 33 2012 187 215
98. D. Tschöpe, M. Hanefeld, and J.J. Meier The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes Cardiovasc Diabetol 12 2013 62
99. A. Zanchi, R. Lehmann, and J. Philippe Antidiabetic drugs and kidney disease - recommendations of the Swiss Society for Endocrinology and Diabetology Swiss Med Wkly 142 2012 w13629
100. H.T. Facundo, and S.P. Jones AMPK activators: not just for diabetes Circ Res 104 2009 282 284